Research Peptides

Colivelin

Colivelin is a hybrid peptide that combines an activity-dependent neurotrophic factor (ADNF)-derived sequence (SALLRSIPA) with a potent humanin derivative (AGA-HNG17). This fusion creates a peptide with synergistic neuroprotective activity that is significantly more potent than either component alone, showing promise in Alzheimer disease and neurodegenerative models.

Technical Specifications

Sequence / StructureSALLRSIPA-AGA(C8R)HNG17 hybrid sequence
Molecular Weight~2800 g/mol
Purity>=98%
AppearanceWhite lyophilized powder
StorageStore at -20C, reconstituted at 2-8C
SolubilitySoluble in water

Application Areas

  • Alzheimer disease research
  • Neuroprotection
  • Memory studies
  • Neurodegenerative disease models
  • Humanin signaling
  • ADNF research

Published Research on Colivelin

Chiba T, Yamada M, Sasabe J, et al. (2009) — Amyloid-beta causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons. Mol Psychiatry. DOI: 10.1038/mp.2008.105

Matsuoka M. (2009) — Humanin; a defender against Alzheimer disease?. Recent Pat CNS Drug Discov. DOI: 10.2174/157488909789104848

Chiba T, Yamada M, Hashimoto Y, et al. (2005) — Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus. J Neurosci. DOI: 10.1523/JNEUROSCI.1348-05.2005

Frequently Asked Questions About Colivelin

A hybrid peptide combining ADNF and humanin derivative sequences for synergistic neuroprotection.

Activates both STAT3 and humanin signaling pathways simultaneously for enhanced neuroprotective efficacy.

>=98% with certificates of analysis.

Alzheimer disease, neuroprotection, memory enhancement, and neurodegenerative disease models.

Lyophilized at -20C, reconstituted at 2-8C.

Yes, competitive bulk pricing available.

Related Research Peptides

Request Price List